← Back to Clinical Trials
Recruiting NCT05874375

UCon Treatment of Overactive Bladder (OAB) in Males

Trial Parameters

Condition Urinary Incontinence
Sponsor InnoCon Medical
Study Type INTERVENTIONAL
Phase N/A
Enrollment 20
Sex MALE
Min Age 18 Years
Max Age N/A
Start Date 2023-10-12
Completion 2026-06-12
Interventions
Urge stimulationTime limited stimulation

Brief Summary

UCon is a medical device for treatment of the symptoms of OAB and fecal incontinence (FI). It electrically stimulates the DGN through the skin to obtain modulated behaviour of the bladder musculature e.g., suppress undesired bladder activity to relieve the symptoms of the patient. This clinical investigation is a randomized, cross-over, single-site, prospective, early feasibility study, which is used to evaluate Ucon with respect to its initial clinical safety and device performance in a small number of males with OAB.

Eligibility Criteria

Inclusion Criteria: 1. Subject is ≥ 18 years of age. 2. Subject is male. 3. Subject is diagnosed with OAB 4. Subject is able to communicate, provide feedback, understand and follow instructions during the course of the investigation. Exclusion Criteria: 1. Subject is medically unstable (acute illness or complications of a chronic condition that might affect the subject's participation in the investigation). 2. Subject has a Post Void Residual (PVR) of more than 100 ml or a Bladder Voiding Efficiency (BVE) of less than 75% (measured by uroflowmetry as the ratio of voided volume (VV) and total bladder capacity (VV+PVR)). 3. Subject has an active infection in the genital area incl. skin infections and urinary tract infection. 4. Subject has had botulinum toxin (BOTOX) treatment in the pelvic region within 6 months. 5. Subject has used antimuscarinics or β3 agonists within 14 days weeks\*. 6. Subject has an implanted pacemaker, implantable drug pump or other active medical device (any medi

Related Trials